Technical Articles

The uniqueness of RIPTAC technology lies not only in its "hold and kill" mechanism of action but also in the flexibility and breadth of its target selection. Traditional small-molecule inhibitors require targets to have well-defined active pockets and druggable chemical space; PROTACs demand that target proteins be recognized and degraded by the ubiquitin-proteasome system; whereas RIPTAC's sole requirement for a target protein is—its specific overexpression in tumor cells. This extremely low target threshold enables RIPTAC to potentially target a vast number of proteins previously deemed "undruggable." This article dissects the core scientific challenges in RIPTAC molecular design from two dimensions: target selection logic and the thermodynamics of ternary complex formation.